Back

Bentracimab demonstrates reversal of antiplatelet effects of ticagrelor: impact of hematocrit and generic versions of ticagrelor in vitro

26 August 2022 (08:00 - 19:30)
Organised by:
Congress Presentation Part of: Short and long-term antiplatelet therapy in clinical practice Antiplatelet Drugs ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Professor Ben Curry

MLM Medical Labs, Memphis (United States of America)

7 More presentations in this session

Presentation thumbnail
Short dual antiplatelet therapy duration in high bleeding risk patients undergoing PCI for non-ST-elevation acute coronary syndrome
Doctor D. Cao (Milan, IT)
Abstract Slides
Presentation thumbnail
CYP2C19 loss-of-function alleles and the use of omeprazole or esomeprazole increase the risk of cardiovascular outcomes in patients using clopidogrel - a real-world study
Mr M. Ritvos (Helsinki, FI)
Abstract Slides
Presentation thumbnail
Intravenous antiplatelet therapy with cangrelor vs. tirofiban in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention
Doctor M. Centore (Salerno, IT)
Abstract Slides
Presentation thumbnail
Comparing dual antiplatelet therapy strategies post-acute coronary syndrome: network meta-analysis
Doctor R. Turgeon (Vancouver, CA)
Abstract Slides
Presentation thumbnail
Thirty-days versus standard duration of dual antiplatelet treatment after percutaneous coronary interventions: a systematic review and meta-analysis
Doctor A. Apostolos (London, GB)
Abstract Slides

Access the full session

Session thumbnail
Short and long-term antiplatelet therapy in clinical practice

The Event

Event poster

ESC Congress 2022

26 August - 29 August 2022
You may be interested in
thumbnail
Congress Presentation
State-of-the-art lecture on adjunctive antiplatelet therapy for patients undergoing percutaneous coronary intervention
thumbnail
Congress Presentation
State-of-the-art lecture on pharmacotherapy for acute coronary syndromes
thumbnail
Webinar
Aspirin treatment for mitigating thrombotic risk across the cardiovascular risk continuum

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources